Spectral library searching is one of the most sensitive strategies available for peptide identification. Rather than comparing an experimental tandem mass spectrum against theoretically predicted fragments, a library search compares the query spectrum against a curated collection of previously observed, empirically validated spectra. Because real spectra capture the idiosyncrasies of fragmentation behavior, ion intensities and instrument-specific artifacts, library-based matches are typically more reliable and more sensitive than theoretical database searches. This advantage, however, comes with a limitation: the library only contains spectra for the peptide forms that were catalogued when it was built. If a peptide in the sample carries a modification that was not represented in the library, the corresponding spectrum will be absent and the peptide will go unidentified.

Open modification search was developed precisely to close that gap. Instead of restricting the search to a narrow window of precursor mass differences, an open search tolerates arbitrarily large mass shifts between the query precursor and candidate library entries, allowing a modified query spectrum to be matched against the unmodified spectrum of the same peptide sequence, with the mass difference then interpreted as the modification. The strategy has proven effective for discovering unexpected post-translational modifications, but it introduces a subtle and problematic side effect. When a modification is attached to a peptide, it does not only shift the precursor mass; it can also shift the masses of the fragment ions that contain the modified residue. Those fragment-ion shifts distort the spectral similarity calculations at the heart of library matching, degrading alignment between the query and library spectra and causing true matches to score poorly against incorrect candidates.

The authors of the new study identified this failure mode as the central weakness of existing open spectral library search methods. During the candidate retrieval stage, in which the search engine must decide which library spectra deserve detailed scoring, conventional approaches do not adequately account for modification-induced fragment-ion shifts. The consequence is that genuinely modified peptides may never even reach the scoring stage, because their distorted spectra fail to rank the correct library entry among the top candidates. The problem is especially acute for peptides carrying modifications near the C-terminus, where a large fraction of fragment ions in typical fragmentation modes include the modified site and are therefore displaced by the mass shift. For these species, conventional candidate retrieval is particularly susceptible to losing the true match in the noise.

POMS tackles this weakness by changing how candidate spectra are represented and compared. The framework integrates complementary spectral representations with sequence-derived theoretical fragment features, producing a composite description of each library spectrum that is robust to the displacement of fragment ions caused by a modification. Because the theoretical features are derived from the peptide sequence itself, they provide a stable anchor for alignment even when the experimental spectrum’s observed fragments have been shifted by an unanticipated mass. This dual-representation strategy compensates for the modification-induced shifts during alignment, improves the correspondence between query and library spectra, and increases robustness to variability in the position of the modification site along the peptide backbone.

To assess the practical impact of these design choices, the researchers benchmarked POMS on large-scale human tandem mass spectrometry datasets, including data derived from human embryonic kidney cells. The results were striking. During the open search phase, POMS yielded up to approximately eight percent more peptide identifications than conventional candidate retrieval methods, a substantial gain in a field where every additional identification represents hard-won biological information. Cross-validation against independent database search engines, a standard approach for verifying that newly reported matches are credible rather than artifacts of a particular algorithm, demonstrated a greater than five percent increase in consistent peptide identifications, indicating that the additional matches reported by POMS are corroborated by orthogonal search strategies.

The gains were most pronounced for the peptide classes that conventional methods struggle with most. POMS substantially improved the identification of peptides carrying C-terminal modifications, exactly the category for which modification-induced fragment-ion shifts are most disruptive to conventional candidate retrieval. This matters because many biologically important modification events occur at or near peptide termini, and their systematic under-detection can skew downstream biological interpretation. By recovering these difficult cases, POMS expands the visible inventory of the proteome and reduces a form of detection bias that has been embedded in open search workflows.

An important consideration for any computational tool intended for large-scale proteomics is whether its added sensitivity comes at an unacceptable computational cost. The authors emphasize that POMS incorporates modification-aware candidate retrieval while preserving computational efficiency, making it a practical option for the very large datasets that characterize modern proteomics experiments. The framework is designed to slot into existing spectral library search workflows rather than requiring laboratories to rebuild their pipelines from scratch, lowering the barrier to adoption. In addition, the software exploits approximate nearest neighbor techniques to manage the scale of library searching, ensuring that the richer spectral representations do not translate into prohibitive search times.

For the broader proteomics community, the implications extend beyond a simple sensitivity bump. Post-translational modifications govern nearly every aspect of protein function, from enzyme activation and signal transduction to protein degradation and disease states, and mass spectrometry remains the dominant technology for mapping them at scale. Open modification search has been a transformative idea, but its full potential has been throttled by the candidate-retrieval bottleneck that POMS directly addresses. By making the earliest and most consequential step of the search modification-aware, the framework increases both the sensitivity and the reliability of modification-tolerant searching, offering researchers a sharper lens for PTM discovery in contexts ranging from basic cell biology to biomarker research.

The tool is publicly available to the research community under a CC BY-NC-SA 4.0 license through the GitHub repository maintained by the Korea Basic Science Institute, allowing laboratories to evaluate it against their own data and integrate it into their analysis pipelines. The work was supported by the Korea Basic Science Institute and by grants from the National Research Foundation of Korea funded by the Korean Ministry of Science and ICT, reflecting a sustained national investment in proteome informatics. As spectral libraries continue to grow and instruments generate ever-larger volumes of tandem mass spectra, methods such as POMS that combine domain-aware algorithm design with practical efficiency are likely to define the next generation of peptide identification tools, helping researchers extract more complete and more accurate pictures of the modified proteome from the data they already collect.

Subject of Research: Modification-aware open spectral library search for identification of post-translationally modified peptides in tandem mass spectrometry

Article Title: POMS enhances open spectral library search for identification of modified peptides

Article References: Seo, Y., Paek, E., & Na, S. (2026). POMS enhances open spectral library search for identification of modified peptides. BMC Bioinformatics. https://doi.org/10.1186/s12859-026-06672-0

Image Credits: AI Generated

DOI: 10.1186/s12859-026-06672-0

Keywords: proteomics, tandem mass spectrometry, post-translational modifications, open modification search, spectral library search, peptide identification, modified peptides, fragment-ion shifts, candidate retrieval, proteome informatics, POMS, BMC Bioinformatics

Mass spectrometry-based amyloid typing has earned a reputation as the gold standard for identifying the amyloidogenic protein in tissue deposits. By shredding laser-microdissected amyloid plaques into peptides and reading their mass spectra, laboratories can distinguish among more than thirty amyloid types with a specificity that immunohistochemistry and immunofluorescence simply cannot match. Yet the technique has remained confined largely to a handful of reference laboratories because it depends on nanoflow liquid chromatography, in which solvents are pushed through capillaries with inner diameters measured in tens of micrometers. Nanoflow systems deliver exquisite sensitivity, but they come with steep up-front costs, demanding maintenance, long column equilibration times, and a level of operational complexity that deters routine clinical adoption.

The Stanford team, led by Morgan W. Mann and Fangjun Chen with senior authors Megan L. Troxell and Ruben Y. Luo, set out to re-engineer the workflow so that it could run on the high-flow liquid chromatography systems already humming away in hospital laboratories. Their solution rests on two complementary innovations: a sample preparation method called suspension trapping, known commercially as S-Trap, and an acquisition strategy known as data-independent acquisition, or DIA. Together, these techniques allow the analysis of microdissected amyloid plaques using conventional-flow chromatography coupled to tandem mass spectrometry, without sacrificing the diagnostic accuracy that clinicians rely upon.

Suspension trapping is the quieter revolution of the two. In traditional proteomics sample preparation, proteins extracted from tiny tissue fragments must be digested into peptides through a series of solution exchanges, buffer removals, and cleanups that consume time and lose precious material at every step. The S-Trap approach instead traps proteins on a quartz filter matrix as they precipitate out of an acidic methanol-containing buffer. Digestion enzymes then pass through the trap, generating peptides that are eluted in a single, efficient step. The method is fast, robust, and minimizes sample loss, which matters enormously when the starting material consists of a few thousand cells harvested by laser capture microdissection from a formalin-fixed paraffin-embedded tissue section.

Data-independent acquisition addresses the other half of the problem. In classical data-dependent acquisition, the mass spectrometer selects the most intense ions in each scan for fragmentation, a stochastic process that can miss low-abundance peptides and produces data that are tedious to align across runs. DIA, by contrast, fragments all ions within successive wide mass windows, systematically recording fragment spectra for essentially everything in the sample. The resulting data are reconstructed computationally against spectral libraries, yielding consistent and quantitative peptide identifications. Because DIA tolerates the higher flow rates, wider chromatographic peaks, and greater sample loads of high-flow chromatography, it made the leap away from nanoflow feasible rather than merely aspirational.

To translate raw proteomic data into a diagnosis, the researchers also developed a custom selection heuristic that sifts through the hundreds of proteins detected in each plaque and identifies the most likely amyloidogenic culprit. Amyloid deposits are not pure; they sweep up serum proteins, immunoglobulin fragments, and extracellular matrix components as they form. Distinguishing the genuine amyloidogenic protein from innocent bystanders requires weighing total protein abundance, the presence of type-specific signature peptides, and the biological plausibility of each candidate. The heuristic automates this judgment, reducing an expert curation task that could take hours into a reproducible computational step suitable for a busy clinical workflow.

The performance data are striking. Working with laser capture microdissected plaques from 47 patient samples, 10 from cardiac biopsies and 37 from renal biopsies, the team split the material into a training set of 25 samples and an independent testing set of 22. The high-flow LC-DIA-MS/MS method identified the amyloidogenic protein in approximately 96 percent of plaques in both sets, a success rate comparable to established nanoflow approaches. The two inaccuracies observed across the cohort both traced to difficulties in identifying immunoglobulin lambda proteins, once in a specimen obtained after treatment had altered the composition of the deposits and once in a plaque containing two distinct amyloid types simultaneously. These edge cases, the authors note, define the boundaries of the method rather than undermining its general utility.

Reducing the sample preparation workflow to under eight hours carries practical significance beyond convenience. Amyloidosis is increasingly recognized as an urgent diagnosis; cardiac involvement can progress rapidly, and new therapies such as transthyretin stabilizers and silencing agents work best when started early. Every hour shaved from the analytical pipeline shortens the time between biopsy and answer. Equally important, the shift to high-flow chromatography means the method can run on instruments of the kind already deployed for clinical chemistry assays, drug monitoring, and newborn screening in hospital laboratories. That compatibility could transform amyloid typing from a rarefied referral test into an accessible diagnostic performed locally, at lower cost and with faster turnaround.

The study, published in Clinical Proteomics, was conducted on remnant patient specimens under approved institutional review board protocols and funded through the Stanford University Department of Pathology’s Test Development Program, underscoring its explicitly clinical orientation. The authors acknowledge one commercial entanglement: a collaborative research relationship between one investigator and Thermo Fisher Scientific, which provided technical support. While the method will still require validation in other laboratories and across broader panels of amyloid types, the combination of suspension trapping, data-independent acquisition, and high-flow chromatography represents a credible path toward democratizing molecular amyloid typing, offering patients everywhere the prospect of a faster, more precise answer to the question their treatment ultimately depends on.

Subject of Research: A high-flow liquid chromatography-tandem mass spectrometry method for typing amyloidosis in clinical laboratories

Article Title: Suspension trapping and data-independent acquisition enable high-flow liquid chromatography-tandem mass spectrometry-based amyloidosis typing in clinical laboratories

Article References: Mann, M. W., Chen, F., Zhu, C., Lu, C., Liang, B., Kambham, N., Troxell, M. L., & Luo, R. Y. (2026). Suspension trapping and data-independent acquisition enable high-flow liquid chromatography-tandem mass spectrometry-based amyloidosis typing in clinical laboratories. Clinical Proteomics. https://doi.org/10.1186/s12014-026-09628-x

Image Credits: AI Generated

DOI: 10.1186/s12014-026-09628-x

Keywords: amyloidosis, mass spectrometry, proteomics, data-independent acquisition, suspension trapping, liquid chromatography, clinical diagnostics, laser capture microdissection, AL amyloidosis, ATTR amyloidosis, tandem mass spectrometry, clinical proteomics